Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.

This study evaluated local treatment with minoxidil 2% watery solution in patients with androgenetic alopecia but did not report detailed clinical outcomes.

This study found that the incidence of major adverse cardiovascular events in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis who received Ixekizumab was low and stable over 3 to 5 years across 25 clinical trials.

This study in rats found that a new hydroxypropyl-β-cyclodextrin formulation of minoxidil reduced the adverse cardiovascular and proliferative effects seen with traditional minoxidil solutions.

This study observed that certain changes in facial "heart representation areas," like eyebrow hair whitening and loss, are associated with cardiovascular issues and may correspond with increased Cardiac Troponin I levels.

There is not enough evidence to support health claims about soy isoflavones.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

This study found that individuals with hospital-treated alopecia areata in Denmark had increased standardized incidence rates of serious infections, herpes zoster infections, lymphoma, cardiovascular events, and death compared to the age- and sex-matched general population.

This case report discusses a 45-year-old Japanese man who developed myocardial infarction while using 1% topical minoxidil for baldness, highlighting the need for caution in patients with cardiovascular disorders.

This review discusses the efficacy of Minoxidil and finasteride for treating androgenetic alopecia and suggests that combined therapy may offer superior results and improved patient adherence despite potential side effects.

Testosterone therapy can help with androgen deficiency in women but should be used with caution and monitoring due to potential risks.

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

This review discusses the genetics and variable phenotypic expression of nonclassic congenital adrenal hyperplasia, and reports no new clinical results; the authors call for further research on long-term health impacts and treatment strategies.

This review discusses the challenges and research gaps in transgender health care, highlighting the need for dedicated research infrastructure and funding to develop a more comprehensive evidence base.

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.

This study highlights the challenges faced by women with PCOS and emphasizes the importance of lifestyle changes, such as diet and weight loss, as the primary treatment strategy to manage symptoms and reduce associated health risks.

This review discusses the impact of various drugs on metabolic parameters in women with polycystic ovary syndrome, without reporting new clinical findings.

This research found that physical activity may modestly improve insulin resistance, lipids, and fitness in women with PCOS, though the evidence remains weak and more robust studies are needed.

This study found that oral minoxidil 5 mg daily significantly improves hair growth in men with androgenetic alopecia, although common side effects include hypertrichosis and pedal edema.

This study found that low-dose oral minoxidil (≤5 mg/day) effectively increased hair number and diameter in men and women with androgenetic alopecia, and was generally well-tolerated with mostly mild adverse effects, although serious complications were rare and associated mainly with pre-existing heart conditions.

This review discusses emerging concepts in PCOS from the AEPCOS 2010 meeting and reports no clinical findings; it suggests that the transition of care in congenital adrenal hyperplasia could inform PCOS adolescent care.

AGA patients have higher rates of metabolic syndrome and carotid atheromatosis, suggesting early screening and prevention is important.

This article reviews the use of cross-sex hormonal therapy in transmen and reports that it is reasonably safe, suggesting monitoring should be frequent initially but can be less frequent over time.

This review discusses factors influencing hair pigmentation and the etiology of canities, noting the lack of clarity in underlying mechanisms and calling for further research on treatment options.

This review discusses the diagnostic criteria and management strategies for Polycystic Ovary Syndrome (PCOS) and highlights the need for comprehensive clinical assessment, but does not report new clinical findings.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.